ALKS 2680 Dose 3

Drug identity checked against registry records

Also recorded as Alixorexton

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2NCT07502443Alkermes, Inc.Phase 3Recruiting2027-05Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.